Incidence of Antiphospholipid Antibodies in Patients With Immune Thrombocytopenia and Correlation With Treatment With Steroids in North Indian Population
Authors:
- 10 April 2016
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 23 (6) , 657-662
Abstract
Introduction: Antiphospholipid antibodies (APLAs) have been variably reported in 14% to 75% of patients with immune thrombocytopenia (ITP). There is lack of Indian data on incidence of APLA in ITP. Objective: We studied the incidence of APLA in patients with pediatric and adult Indian ITP. Materials and Methods: We prospectively studied 100 patients including acute (n = 37), persistent (n = 13), and chronic (n = 50) ITP. Male to female ratio was 1.22:1. Median age was 18 years (1.5-56). All patients underwent investigations for lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG) and IgM antibodies, and anti-β2 glycoprotein 1 (β2GP1) IgG and IgM antibodies. Patients with secondary ITP were excluded. Bleeding manifestations were recorded. Patients with acute and persistent ITP were assessed for steroid response. Response rates were compared between APLA-positive and APLA-negative patients. Results: Antiphospholipid antibodies were detected in ∼12% of patients with ITP: 8.1% (3 of 37) in acute, 0% (0 of 13) in persistent, and 18% (9 of 50) in chronic ITP. Anti-β2GP1 antibodies were most frequent (9%). Only 2 patients each were positive for anti-aCL antibodies and LA. Although platelet counts were significantly higher in APLA-positive patients, there was no significant difference in bleeding between the APLA-positive versus APLA-negative patients with ITP. There was also no significant difference in steroid response between APLA-positive and APLA-negative patients with acute/persistent ITP. In the short follow-up (median 8 months), none of the APLA-positive patients developed thrombosis. Conclusions: Incidence of APLA in Indian population was lower than reported in the West, which indicates that not all patients of ITP need to be subjected to these manifestations upfront at diagnosis.Keywords
This publication has 18 references indexed in Scilit:
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Antiphospholipid antibodies in adults with immune thrombocytopenic purpuraBritish Journal of Haematology, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remissionBritish Journal of Haematology, 2005
- Lupus anticoagulant in immune thrombocytopenic purpuraIndian Journal of Pediatrics, 2004
- Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort studyBlood, 2001
- Characteristics of the Clinical Findings in Patients with Idiopathic Thrombocytopenic Purpura Who are Positive for Anti-phospholipid Antibodies.Internal Medicine, 1997
- Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranesEuropean Journal of Haematology, 1996
- Anticardiolipin antibodies in autoimmune thrombocytopenic purpuraBritish Journal of Haematology, 1985